Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCobo, J
dc.identifier.citationRev Esp Quimioter.2018 Sep;(31 Suppl 1):27-31
dc.description.abstractDuring the last decade there have been many changes and advances in the research on Clostridium difficile infection (CDI). We have improved diagnostic and therapeutic tools and, at the same time, we have learned that the CDI implies, especially in the most vulnerable patients, an important morbidity. CDI has traditionally been undervalued and it is widely dispersed in hospitals. Surely, there is inertness in its management and there are also broad areas of improvement. If we add to this the high cost of the new drugs and the practical difficulties to implement the faecal microbiota transplant, we realize that we may not be taking full advantage of all the opportunities to improve patient's outcomes. The implementation of policies that favour the supervision of all CDI cases by an expert in infectious diseases will contribute to a better global management of this important disease.
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshClostridium Infections
dc.subject.meshClostridium difficile
dc.titleA comprehensive approach for the patient with Clostridium difficile infection.
dc.format.volume31 Suppl 1
dc.identifier.journalRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
dc.pubmedtypeJournal Article
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC6459568.pdf224.02 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.